Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001786:Blood Glucose / Q000378:metabolism; D002386:Cataract / Q000188:drug therapy; D055598:Chemical Phenomena; D002621:Chemistry; D003316:Corneal Diseases / Q000188:drug therapy; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy; D003929:Diabetic Neuropathies / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D004195:Disease Models, Animal; D005449:Fluorenes / Q000627:therapeutic use; D005690:Galactose / Q000378:metabolism; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D048289:Imidazolidines; D008958:Models, Molecular; D009281:Naphthalenes / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D012236:Rhodanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013012:Sorbitol / Q000378:metabolism; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*; D053778:Thiazolidines; D014018:Tissue Distribution
D001786:Blood Glucose; D005449:Fluorenes; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; D009281:Naphthalenes; D010793:Phthalazines; D053778:Thiazolidines; C040550:tolrestat; C042829:ponalrestat; C038131:epalrestat; C045887:alconil; D013012:Sorbitol; D012236:Rhodanine; C037070:M 79175; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase; C026411:sorbinil; D005690:Galactose